These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 23112559)

  • 1. A de novo germline MLH1 mutation in a Lynch syndrome patient with discordant immunohistochemical and molecular biology test results.
    Airaud F; Küry S; Valo I; Maury I; Bonneau D; Ingster O; Bezieau S
    World J Gastroenterol; 2012 Oct; 18(39):5635-9. PubMed ID: 23112559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. De novo constitutional MLH1 epimutations confer early-onset colorectal cancer in two new sporadic Lynch syndrome cases, with derivation of the epimutation on the paternal allele in one.
    Goel A; Nguyen TP; Leung HC; Nagasaka T; Rhees J; Hotchkiss E; Arnold M; Banerji P; Koi M; Kwok CT; Packham D; Lipton L; Boland CR; Ward RL; Hitchins MP
    Int J Cancer; 2011 Feb; 128(4):869-78. PubMed ID: 20473912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Germline MLH1 Mutations Are Frequently Identified in Lynch Syndrome Patients With Colorectal and Endometrial Carcinoma Demonstrating Isolated Loss of PMS2 Immunohistochemical Expression.
    Dudley B; Brand RE; Thull D; Bahary N; Nikiforova MN; Pai RK
    Am J Surg Pathol; 2015 Aug; 39(8):1114-20. PubMed ID: 25871621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study.
    Goodfellow PJ; Billingsley CC; Lankes HA; Ali S; Cohn DE; Broaddus RJ; Ramirez N; Pritchard CC; Hampel H; Chassen AS; Simmons LV; Schmidt AP; Gao F; Brinton LA; Backes F; Landrum LM; Geller MA; DiSilvestro PA; Pearl ML; Lele SB; Powell MA; Zaino RJ; Mutch D
    J Clin Oncol; 2015 Dec; 33(36):4301-8. PubMed ID: 26552419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Null pattern" of immunoreactivity in a Lynch syndrome-associated colon cancer due to germline MSH2 mutation and somatic MLH1 hypermethylation.
    Hagen CE; Lefferts J; Hornick JL; Srivastava A
    Am J Surg Pathol; 2011 Dec; 35(12):1902-5. PubMed ID: 22067334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two new MLH1 germline mutations in Brazilian Lynch syndrome families.
    Dominguez MV; Bastos EP; Santos EM; Oliveira LP; Ferreira FO; Carraro DM; Rossi BM
    Int J Colorectal Dis; 2008 Dec; 23(12):1263-4. PubMed ID: 18594839
    [No Abstract]   [Full Text] [Related]  

  • 7. Selection of patients with germline MLH1 mutated Lynch syndrome by determination of MLH1 methylation and BRAF mutation.
    Bouzourene H; Hutter P; Losi L; Martin P; Benhattar J
    Fam Cancer; 2010 Jun; 9(2):167-72. PubMed ID: 19949877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spectrum of MLH1 and MSH2 mutations in Chilean families with suspected Lynch syndrome.
    Alvarez K; Hurtado C; Hevia MA; Wielandt AM; de la Fuente M; Church J; Carvallo P; López-Köstner F
    Dis Colon Rectum; 2010 Apr; 53(4):450-9. PubMed ID: 20305446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer.
    Capper D; Voigt A; Bozukova G; Ahadova A; Kickingereder P; von Deimling A; von Knebel Doeberitz M; Kloor M
    Int J Cancer; 2013 Oct; 133(7):1624-30. PubMed ID: 23553055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome.
    Niessen RC; Hofstra RM; Westers H; Ligtenberg MJ; Kooi K; Jager PO; de Groote ML; Dijkhuizen T; Olderode-Berends MJ; Hollema H; Kleibeuker JH; Sijmons RH
    Genes Chromosomes Cancer; 2009 Aug; 48(8):737-44. PubMed ID: 19455606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline mutation analysis of MLH1 and MSH2 in Malaysian Lynch syndrome patients.
    Zahary MN; Kaur G; Abu Hassan MR; Singh H; Naik VR; Ankathil R
    World J Gastroenterol; 2012 Feb; 18(8):814-20. PubMed ID: 22371642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer.
    Lu KH; Schorge JO; Rodabaugh KJ; Daniels MS; Sun CC; Soliman PT; White KG; Luthra R; Gershenson DM; Broaddus RR
    J Clin Oncol; 2007 Nov; 25(33):5158-64. PubMed ID: 17925543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of cancer in cases of suspected lynch syndrome without germline mutation.
    Rodríguez-Soler M; Pérez-Carbonell L; Guarinos C; Zapater P; Castillejo A; Barberá VM; Juárez M; Bessa X; Xicola RM; Clofent J; Bujanda L; Balaguer F; Reñé JM; de-Castro L; Marín-Gabriel JC; Lanas A; Cubiella J; Nicolás-Pérez D; Brea-Fernández A; Castellví-Bel S; Alenda C; Ruiz-Ponte C; Carracedo A; Castells A; Andreu M; Llor X; Soto JL; Payá A; Jover R
    Gastroenterology; 2013 May; 144(5):926-932.e1; quiz e13-4. PubMed ID: 23354017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for germline mutations of MLH1, MSH2, MSH6 and PMS2 genes in Slovenian colorectal cancer patients: implications for a population specific detection strategy of Lynch syndrome.
    Berginc G; Bracko M; Ravnik-Glavac M; Glavac D
    Fam Cancer; 2009; 8(4):421-9. PubMed ID: 19526325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Segregation of a novel MLH1 mutation in an Iranian Lynch syndrome family.
    Ghafouri-Fard S; Fardaei M; Lankarani KB; Miryounesi M
    Gene; 2015 Oct; 570(2):304-5. PubMed ID: 26149658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficient molecular screening of Lynch syndrome by specific 3' promoter methylation of the MLH1 or BRAF mutation in colorectal cancer with high-frequency microsatellite instability.
    Nakagawa H; Nagasaka T; Cullings HM; Notohara K; Hoshijima N; Young J; Lynch HT; Tanaka N; Matsubara N
    Oncol Rep; 2009 Jun; 21(6):1577-83. PubMed ID: 19424639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lynch syndrome in Tunisia: first description of clinical features and germline mutations.
    Moussa SA; Moussa A; Kourda N; Mezlini A; Abdelli N; Zerimech F; Najjar T; Jilani SB; Porchet N; Ayed FB; Manai M; Buisine MP
    Int J Colorectal Dis; 2011 Apr; 26(4):455-67. PubMed ID: 21311894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer).
    Hampel H; Frankel WL; Martin E; Arnold M; Khanduja K; Kuebler P; Nakagawa H; Sotamaa K; Prior TW; Westman J; Panescu J; Fix D; Lockman J; Comeras I; de la Chapelle A
    N Engl J Med; 2005 May; 352(18):1851-60. PubMed ID: 15872200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epitope-positive truncating MLH1 mutation and loss of PMS2: implications for IHC-directed genetic testing for Lynch syndrome.
    Zighelboim I; Powell MA; Babb SA; Whelan AJ; Schmidt AP; Clendenning M; Senter L; Thibodeau SN; de la Chapelle A; Goodfellow PJ
    Fam Cancer; 2009; 8(4):501-4. PubMed ID: 19672700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MLH1 germline epimutations in selected patients with early-onset non-polyposis colorectal cancer.
    Valle L; Carbonell P; Fernandez V; Dotor AM; Sanz M; Benitez J; Urioste M
    Clin Genet; 2007 Mar; 71(3):232-7. PubMed ID: 17309645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.